For example, in previous trials investigating the usefulness of IV t-PA, the proportions of patients with mRS score of 0–1 at 90 days were 39% in the National Institute of Neurological Disorders and Stroke study [13], 52.4% in ECASS III [12], and 39% in Safe Implementation of Thrombolysis in Stroke-Monitoring Study [17]. This evidence concerns the gene PLAT and stroke disorder.